Corrigendum: Defining the effectiveness of antimalarial chemotherapy: Investigation of the lag in parasite clearance following drug administration (Journal of Infectious Diseases (2016) 214 (753-761) DOI: 10.1093/infdis/jiw234);Defining the effectiveness of antimalarial chemotherapy: Investigation of the lag in parasite clearance following drug administration

Journal of Infectious Diseases

Volumn 214, Issue 5, 2016, Pages 753-761

  Khoury, David S ^a   Cromer, Deborah ^a   Möhrle, Jörg J ^d   McCarthy, James S ^b,c   Davenport, Miles P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d Switzerland   (Switzerland)

Author keywords

Antimalarial; Blood stage; Drug efficacy; Human challenge; Lag phase; Malaria; Mathematical modelling; Plasmodium falciparum

Indexed keywords

ANTIMALARIAL AGENT; ANTIPARASITIC AGENT; ARTEMETHER PLUS BENFLUMETOL; ATOVAQUONE PLUS PROGUANIL; DSM 265; FERROQUINE; MEFLOQUINE; OZ 439; PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG;

ABSORPTION LAG TIME; ANTIMALARIAL ACTIVITY; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALARIA FALCIPARUM; NONHUMAN; PARASITE CLEARANCE; PARASITE KINETICS; PARASITE PHENOMENA AND FUNCTIONS; PARASITEMIA; PLASMODIUM FALCIPARUM 3D7; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TIME TO TREATMENT; TREATMENT RESPONSE; ANIMAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; PARASITOLOGY; PLASMODIUM FALCIPARUM; REAL TIME POLYMERASE CHAIN REACTION; TIME FACTOR; TREATMENT OUTCOME; VOLUNTEER;

ANIMALS; ANTIMALARIALS; COHORT STUDIES; HUMANS; MALARIA, FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT OUTCOME; VOLUNTEERS;

EID: 84988942533     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy729     Document Type: Erratum

References (35)

1. Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995; 332:1399-404.
2. Lackritz EM, Campbell CC, Ruebush TK, et al. Effect of blood transfusion on survival among children in a Kenyan hospital. Lancet 1992; 340:524-8.
3. Bojang KA, van Hensbroek MB, Palmer A, Banya WA, Jaffar S, Greenwood BM. Predictors of mortality in Gambian children with severe malaria anaemia. Ann Trop Paediatr 1997; 17:355-9.
4. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 2011; 10:339.
5. White NJ, Chapman D,Watt G. The effects of multiplication and synchronicity on the vascular distribution of parasites in falciparum malaria. Trans R Soc Trop Med Hyg 1992; 86:590-7.
6. White NJ. The parasite clearance curve. Malar J 2011; 10:278.
7. Silachamroon U, Phumratanaprapin W, Krudsood S, et al. Frequency of early rising parasitemia in falciparum malaria treated with artemisinin derivatives. Southeast Asian J Trop Med Public Health 2001; 32:50-6.
8. Gachot B, Houze S, Le Bras J, Charmot G, Bédos JP, Vachon F. Possible prognostic significance of a brief rise in parasitaemia following quinine treatment of severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 1996; 90:388-90.
9. Farnert A, Snounou G, Rooth I, Bjorkman A. Daily dynamics of Plasmodium falciparum subpopulations in asymptomatic children in a holoendemic area. Am J Trop Med Hyg 1997; 56:538-47.
10. Dondorp AM, Fanello CI, Hendriksen ICE, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647-57.
11. Ndour PA, Lopera-Mesa TM, Diakité SAS, et al. Plasmodium falciparum clearance is rapid and pitting independent in Immune malian children treated with artesunate for malaria. J Infect Dis 2015; 211:290-7.
12. Ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993; 76:85-95.
13. Wilson DW, Langer C, Goodman CD, McFadden GI, Beeson JG. Defining the timing of action of antimalarial drugs against Plasmodium falciparum. Antimicrob Agents Chemother 2013; 57:1455-67.
14. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41:1413.
15. White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 1994; 88 (pl 1):S41-3.
16. Rockett RJ, Tozer SJ, Peatey C, et al. A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers. Malar J 2011; 10:48.
17. McCarthy JS, Sekuloski S, Griffin PM, et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One 2011; 6:e21914.
18. Sanz LM, Crespo B, De-Cózar C, et al. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS One 2012; 7: e30949.
19. Nakazawa S, Maoka T, Uemura H, Ito Y, Kanbara H. Malaria parasites giving rise to recrudescence in vitro. Antimicrob Agents Chemother 2002; 46:958-65.
20. Marquart L, Baker M, O'Rourke P, McCarthy JS. Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. Antimicrob Agents Chemother 2015; 59:4249-59.
21. Barends M, Jaidee A, Khaohirun N, Singhasivanon P, Nosten F. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar J 2007; 6:81.
22. Held J, Supan C, Salazar CLO, et al. Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Lancet Infect Dis 2015; 12:1409-19.
23. Charman SA, Arbe-Barnes S, Bathurst IC, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A 2011; 108:4400-5.
24. Phillips MA, Lotharius J, Marsh K, et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med 2015; 7:296ra111.
25. Hall J. Linear Deming regression. MATLAB Central File Exchange, 2011. Accessed 23 March 2016.
26. Dogovski C, Xie SC, Burgio G, et al. Targeting the cell stress response of plasmodium falciparum to overcome artemisinin resistance. PLoS Biol 2015; 13:e1002132.
27. Douglas AD, Edwards NJ, Duncan CJA, et al. Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection. J Infect Dis 2013; 208:340-5.
28. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379:1960-6.
29. Geary TG, Divo AA, Jensen JB. Stage specific actions of antimalarial drugs on Plasmodium falciparum in culture. Am J Trop Med Hyg 1989; 40:240-4.
30. Silamut K, White NJ. Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg 1993; 87:436-43.
31. Newton PN, Stepniewska K, Dondorp A, et al. Prognostic indicators in adults hospitalized with falciparum malaria in Western Thailand. Malar J 2013; 12:229.
32. Mok S, Ashley EA, Ferreira PE, et al. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 2014; 347:431-5.
33. Pelle KG, Oh K, Buchholz K, et al. Transcriptional profiling defines dynamics of parasite tissue sequestration during malaria infection. Genome Med 2015; 7:19.
34. Watt G, Shanks GD, Phintuyothin P. Prognostic significance of rises in parasitemia during treatment of falciparum-malaria. Trans R Soc Trop Med Hyg 1992; 86:359-60.
35. World Health Organization (WHO). Guidelines for the treatment of malaria. Geneva: WHO, 2010.